Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Biofluid Biopsies

Charles Cantor's Biography

Charles Cantor, Chief Scientific Officer, Sequenom Inc

Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc. He is also founder of SelectX Pharmaceuticals, a drug discovery company based in the Boston area; Retrotope, an anti-aging company; and DiThera, a biotherapeutic company. He is co-director of the Center for Advanced Biotechnology at Boston University, and professor emeritus of Biomedical Engineering. Dr. Cantor has held positions at Columbia University and University of California at Berkeley, and was also director of the Human Genome Center of the Department of Energy at Lawrence Berkeley Laboratory. He has published more than 450 peer-reviewed articles, has been granted more than 60 patents. He co-authored a three-volume textbook on Biophysical Chemistry and the first textbook on Genomics: The Science and Technology of the Human Genome Project. He sits on the advisory boards of more than 15 national and international organizations and is a member of the National Academy of Sciences.

Charles Cantor Image

Prospects for Noninvasive Liquid Biopsies in Cancer and Other Diseases

Tuesday, 28 October 2014 at 17:30

Add to Calendar ▼2014-10-27 00:00:002014-10-27 01:00:00Europe/LondonTitle to be

It is now clear that body fluids like blood, urine and saliva contain diagnostically useful nucleic acid molecular markers from remote sites in the body. Noninvasive prenatal diagnostics detecting fetal DNA in maternal plasma has become the standard of care. In this lecture, I will show that similar diagnostics seem possible in cancer and eventually should become possible in many other diseases. Because the markers are present at very low concentrations all markers of interest must be analyzed simultaneously from one single sample. Next generation DNA sequencing works well for this application but is still too costly to make many repeat measurements.  Nucleic acid mass spectrometry is a great companion to NGS because these measurements are easy to implement and inexpensive. It should be possible to monitor patients frequently enough by liquid biopsies to create and test dynamical models how how therapy is affecting the disease process.

Add to Calendar ▼2014-10-27 00:00:002014-10-28 00:00:00Europe/LondonBiofluid